Unknown

Dataset Information

0

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.


ABSTRACT: In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ?65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ?6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.

SUBMITTER: Arcaini L 

PROVIDER: S-EPMC5814930 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Arcaini Luca L   Lamy Thierry T   Walewski Jan J   Belada David D   Mayer Jiri J   Radford John J   Jurczak Wojciech W   Morschhauser Franck F   Alexeeva Julia J   Rule Simon S   Cabeçadas José J   Campo Elias E   Pileri Stefano A SA   Biyukov Tsvetan T   Patturajan Meera M   Casadebaig Bravo Marie-Laure ML   Trnĕný Marek M  

British journal of haematology 20171128 2


In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL w  ...[more]

Similar Datasets

| S-EPMC5668956 | biostudies-literature
| S-EPMC6518882 | biostudies-literature
| S-EPMC7643179 | biostudies-literature
| S-EPMC4879693 | biostudies-literature
| S-EPMC6896320 | biostudies-literature
| S-EPMC8171498 | biostudies-literature
| S-EPMC4260977 | biostudies-literature
| S-EPMC3811905 | biostudies-literature
| S-EPMC6494247 | biostudies-literature
| S-EPMC3430086 | biostudies-literature